SAB Biotherapeutics (NASDAQ:SABS) Cut to Strong Sell at Zacks Research

SAB Biotherapeutics (NASDAQ:SABS) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

SABS has been the topic of several other reports. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. HC Wainwright reduced their target price on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday. UBS Group started coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price for the company. Chardan Capital boosted their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Guggenheim started coverage on shares of SAB Biotherapeutics in a research report on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Trading Down 9.6%

Shares of NASDAQ SABS opened at $4.15 on Thursday. The company’s 50 day simple moving average is $4.02 and its 200 day simple moving average is $3.36. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The firm has a market capitalization of $211.44 million, a P/E ratio of -1.79 and a beta of 0.59. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 10.50.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). On average, analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SABS. State of Wyoming bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth about $34,000. State Street Corp acquired a new position in SAB Biotherapeutics during the 4th quarter worth approximately $49,000. ADAR1 Capital Management LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $30,000. Fifth Lane Capital LP bought a new stake in SAB Biotherapeutics during the 4th quarter worth about $56,000. Finally, Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the third quarter valued at approximately $32,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.